Third, our glycemic control estimations demonstrating 87 % achievement of HbA1c ≤ 6.5 % targets with CagriSema in type 2 diabetes populations, coupled with minimal hypoglycemia risk of time-below-range less than 0.5 %, suggest these agents may achieve aggressive glycemic targets previously attainable only with insulin-based regimens but without associated hypoglycemia burden. The gene discussed is INS; the disease is type 2 diabetes mellitus.